Navigation Links
Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009
Date:2/2/2009

Company Increases Full Year Expectations for Revenue Growth

BRAINTREE, Mass., Feb. 2 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) today reported third quarter fiscal 2009 GAAP net revenues of $155 million, up 16%; operating income of $24 million, up 25%; and net earnings per share of $0.62, up 15%. Year-to-date, net revenues are $445 million, up 18%; operating income is $67 million, up 35%; and net earnings per share are $1.73, up 22%.

Excluding restructuring charges in both fiscal 2008 and 2009, third quarter fiscal 2009 adjusted operating income was $25 million, up 20%, and adjusted earnings per share were $0.63, up 10%. Year-to-date, adjusted operating income is $70 million, up 30%, and adjusted earnings per share are $1.80, up 18%.(1)

Brad Nutter, Haemonetics' Chairman and CEO, said, "Despite challenging global economic conditions, we are seeing strength across our diversified product lines. I'm particularly pleased to note that year-to-date reported revenue growth is double digits in all of our geographies. Haemonetics' outlook for the future is strong."

Q3FY09 AND YEAR-TO-DATE FINANCIALS(1)

As noted, Haemonetics' third quarter fiscal 2009 net revenues were $155 million, up 16%. Excluding the effects of currency, third quarter net revenues grew 15%. Year-to-date net revenues are $445 million, up 18%. Excluding the effects of currency, year-to-date net revenues grew 14%. The Company expects the impact of currency to be neutral to revenue growth in the fourth quarter.

Haemonetics also reported third quarter gross profit of $78 million, up 18%. Gross margin grew 90 basis points to 50.4%. Year-to-date adjusted gross profit is $226 million, up 20%. Year-to-date adjusted gross margin is 50.8%, up 100 basis points.

Adjusted operating expenses were $53 million in the quarter, up 17%. Year-to-date adjusted operating expenses are $156 million, up 16%. More than half of the year-to-date expense growth came from the impact of foreign exchange and from acquired businesses whose expenses were not included in fiscal 2008 results.

Third quarter adjusted operating income was $25 million, up 20%, and operating margin grew 50 basis points to 16.0%. Year-to-date adjusted operating income is $70 million, up 30%. Operating margin is 15.7%, up 140 basis points.

Third quarter and year-to-date interest and other income declined due to lower interest rates, exchange rate volatility in the quarter, and lower invested cash as Haemonetics spent $44 million to acquire Haemoscope in November 2007 and $60 million on a share repurchase in the first half of fiscal 2009. Third quarter tax rate was 31.0% as the Company benefited from the $1 million favorable resolution of a tax contingency. Year-to-date tax rate is 32.0%.

Adjusted earnings per share were $0.63, up 10% in the quarter, and are $1.80, up 18% year-to-date.

Haemonetics ended the quarter with $125 million in cash, and $10 million of debt. During the quarter, the Company generated $14 million of free cash flow.

REVENUE GROWTH HIGHLIGHTS

Plasma disposables revenue was $54 million for the quarter, up 30%. Year-to-date plasma disposables revenue is $150 million, up 31%. Haemonetics' plasma business continued to benefit from long-term contracts and from global growth in plasma collections as demand for IVIG increases. Haemonetics expects its plasma business will be an ongoing revenue growth driver for the Company.

Blood bank disposables revenue was $36 million for the quarter, up 10%. Year-to-date blood bank disposables revenue is $108 million, up 8%. Haemonetics' blood bank business benefited from the impact of exchange rates, unit growth in emerging markets, and a contract with Canadian Blood Services which made Haemonetics its preferred provider of platelet collection systems. Haemonetics converted the Canadian Blood Services' blood banks to Haemonetics' technology over the course of the first half of fiscal 2008, realizing the comparative benefit of the conversions in the first half of fiscal 2009.

Red cell disposables revenue was $13 million for the quarter, up 5%. Year-to-date red cell disposables revenue is $37 million, up 7%. Revenue growth in the quarter was driven by the U.S. business and by the MCS(R) mobile collection system.

Software and services revenue was $10 million for the quarter, down 10%. Year-to-date software and services revenue is $30 million, up 1%. Excluding services, software revenue growth was 12% in the quarter and 27% year-to-date. Software growth was driven by implementation of contracts negotiated in fiscal 2008, a new contract with the U.S. Department of Defense, and growth in the plasma industry.

Surgical/diagnostics disposables revenue was $23 million, up 21% for the quarter. Year-to-date surgical/diagnostics disposables revenue is $66 million, up 30%. Haemonetics acquired the TEG(R) Thrombelastograph(R) Hemostasis Analyzer business in November 2007, and the Surgical/Diagnostics revenue benefited from sales of the TEG system in the quarter and year-to-date. The TEG business contributed $5 million in the quarter and $15 million year-to-date.

OrthoPAT(R) orthopedic perioperative autotransfusion system disposables revenue was $9 million for the quarter, level with the third quarter of fiscal 2008. Year-to-date OrthoPAT disposables revenue is $26 million, up 5%.

Equipment revenue was $10 million for the quarter, up 21% and $27 million year-to-date, up 23%. Platelet collection equipment sales were particularly strong in the quarter.

Haemonetics reported balanced double digit revenue growth in all geographies year-to-date, with North American sales up 21%, European sales up 17%, Japanese sales up 11%, and Asian sales up 21%.

FISCAL 2009 GUIDANCE

The Company raised its annual revenue guidance to 15-16% growth (from 12-14% growth) on stronger than planned sales of plasma disposables, blood bank disposables, and equipment sales, with strong contribution from each of the geographies. Adjusted operating income is expected to grow 23-25%, and adjusted earnings per share are expected to be between $2.40 to $2.44, up 14-16%. The Company further expects gross margin improvement of 120 basis points, operating margin improvement of 120 basis points, and a tax rate of 32.5% in the year.

For the full year 2009, the Company expects to generate $40 million of free cash flow.

Haemonetics has refined its fiscal 2009 guidance and posted revised income scenarios reflecting guidance ranges as well as potential fiscal 2009 product line growth on its website at http://www.haemonetics.com/site/content/investor/guidance.asp.

As part of this release, Haemonetics has presented supplemental non-GAAP financial results which exclude restructuring costs in fiscal 2008 and fiscal 2009. Haemonetics believes that these non-GAAP results are useful to investors because it allows for an evaluation of the Company with a focus on the results of our core business.

CONFERENCE CALL

Haemonetics will host a webcast on Monday, February 2nd at 10:00 am Eastern to discuss these results. Interested parties can participate at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=2055218.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

This release contains forward-looking statements that involve risks and uncertainties, including technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers' ordering patterns, the effect of industry consolidation as seen in the plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive. The forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements.

(1) A reconciliation of GAAP to adjusted financial results is included at the end of the financial sections of this press release as well as on the web at http://www.haemonetics.com/investors. In the quarter, Haemonetics incurred $0.4 million in pre-tax restructuring costs. Year-to-date restructuring costs are $2.6 million pre-tax. Adjusted fiscal 2009 guidance excludes a planned $6-7 million, or approximately $0.15-$0.18 per share, of costs to restructure Haemonetics' business, including manufacturing, quality, R&D, and Europe.


                     Haemonetics Corporation Financial Summary
               (Unaudited data in thousands, except per share data)

           Consolidated Statements of Income for the Third Quarter FY09

                                12/27/08 As     12/29/07 As     % Inc/(Dec)
                                  Reported        Reported     vs Prior Year
                                ------------    ------------   --------------
    NET REVENUES                    $155,447        $134,587           15.5%
    Gross profit                      78,296          66,558           17.6%

      R&D                              5,840           5,529            5.6%
      S,G&A                           47,965          41,432           15.8%
    Operating expenses                53,805          46,961           14.6%
                                      ------          ------

    Operating income                  24,491          19,597           25.0%
      Interest income, net               449           1,070          (58.0%)
      Other (expense)/income, net     (1,451)            225         (744.9%)
                                      ------             ---

    Income before taxes               23,489          20,892           12.4%

    Tax expense                        7,273           6,538           11.2%

                                     -------         -------
    NET INCOME                       $16,216         $14,354           13.0%
                                     =======         =======

    Net income per common
     share assuming dilution           $0.62           $0.54           14.5%

    Weighted average number of shares
      Basic                           25,375          25,500
      Diluted                         26,056          26,437

                                                                 Inc/(Dec) vs
                                                                  prior year
                                                                    profit
    Profit Margins:                                                 margin %
                                                                -------------
    Gross profit                        50.4%           49.5%           0.9%
    R&D                                  3.8%            4.1%          (0.3%)
    S,G&A                               30.9%           30.8%           0.1%
    Operating income                    15.8%           14.6%           1.2%
    Income before taxes                 15.1%           15.5%          (0.4%)
    Net income                          10.4%           10.7%          (0.3%)



              Consolidated Statements of Income for FY09 Year-To-Date

                                   12/27/08 As   12/29/07 As      % Inc/(Dec)
                                      Reported      Reported    vs Prior Year
                                   ------------  ------------  --------------
    NET REVENUES                       $445,482      $377,701           17.9%
    Gross profit                        226,022       187,940           20.3%

      R&D                                16,901        18,532          (8.8%)
      S,G&A                             141,687       119,418           18.6%
    Operating expenses                  158,588       137,950           15.0%
                                        -------       -------

    Operating income                     67,434        49,990           34.9%
      Interest income, net                1,569         4,037         (61.1%)
      Other (expense)/income, net        (2,366)        1,905        (224.2%)
                                         ------         -----

    Income before taxes                  66,637        55,932           19.1%

    Tax expense                          21,272        17,733           20.0%

                                        -------       -------
    NET INCOME                          $45,365       $38,199           18.8%
                                        =======       =======

    Net income per common share
     assuming dilution                    $1.73         $1.43           21.5%

    Weighted average number
     of shares
      Basic                              25,340        25,881
      Diluted                            26,163        26,776

                                                                Inc/(Dec) vs
                                                                  prior year
                                                                    profit
    Profit Margins:                                                margin %
                                                                -------------
    Gross profit                           50.7%         49.8%           0.9%
    R&D                                     3.8%          4.9%         (1.1%)
    S,G&A                                  31.8%         31.6%           0.2%
    Operating income                       15.1%         13.2%           1.9%
    Income before taxes                    15.0%         14.8%           0.2%
    Net income                             10.2%         10.1%           0.1%


      Operating expense as % of
       net Revenue                         35.6%         36.5%
        Arbitration Award Income            0.0%          0.0%

      EPS to 3 decimals                  $1.734        $1.427           21.5%



       Revenue Analysis for the Third Quarter and Year-To-Date FY09

                                          Third Quarter
                                          -------------
                                                            % Increase
                              12/27/08 As   12/29/07 As      vs. Prior
                               Reported      Reported          Year
                              ------------  ------------    ----------
    Revenues by Geography
      United States              $73,448       $61,481          19.5%
      International              $81,999       $73,106          12.2%
                                 -------       -------
      Net Revenues              $155,447      $134,587          15.5%
                                ========      ========

    Disposable Revenues by
     Product Family

    Donor:
      Plasma                     $53,594       $41,253          29.9%
      Blood Bank                 $36,435       $33,207           9.7%
      Red Cell                   $13,051       $12,478           4.6%
                                 -------       -------
                                $103,080       $86,938          18.6%
                                --------       -------
    Patient:
      Surgical / Diagnostic      $22,967       $18,981          21.0%
      OrthoPAT                    $9,112        $9,086           0.3%
                                  ------        ------
                                 $32,079       $28,067          14.3%
                                 -------       -------

      Subtotal                  $135,159      $115,005          17.5%

    Equipment                    $10,246        $8,485          20.8%
    Software & Services          $10,042       $11,097          (9.5%)
                                 -------       -------
    Net Revenues                $155,447      $134,587          15.5%
                                ========      ========



                                        Nine Months Ended
                                        -----------------
                                                           % Increase
                              12/27/08 As   12/29/07 As      vs. Prior
                               Reported      Reported          Year
                            ------------  ------------     ----------
    Revenues by Geography
      United States             $205,748      $170,085          21.0%
      International             $239,734      $207,616          15.5%
                                --------      --------
      Net Revenues              $445,482      $377,701          17.9%
                                ========      ========

    Disposable Revenues by
     Product Family

    Donor:
      Plasma                    $150,386      $114,788          31.0%
      Blood Bank                $108,388      $100,399           8.0%
      Red Cell                   $36,651       $34,257           7.0%
                                 -------       -------
                                $295,425      $249,444          18.4%
                                --------      --------
    Patient:
      Surgical / Diagnostic      $66,077       $50,907          29.8%
      OrthoPAT                   $26,301       $25,122           4.7%
                                 -------       -------
                                 $92,378       $76,029          21.5%
                                 -------       -------

      Subtotal                  $387,803      $325,473          19.2%

    Equipment                    $27,388       $22,286          22.9%
    Software & Services          $30,291       $29,942           1.2%
                                 -------       -------
    Net Revenues                $445,482      $377,701          17.9%
                                ========      ========




                   Consolidated Balance Sheets


                                       Period ending
                                ---------------------------
                                12/27/08            3/29/08
                                --------            -------

    Assets
    ------
    Cash & cash equivalents      $125,325            $133,553
    Accounts receivable, net      124,575             120,252
    Inventories, net               73,557              65,388
    Other current assets           30,435              40,241
                                   ------              ------
      Total current assets        353,892             359,434
    Net PP&E                      129,470             116,484
    Other assets                  138,986             133,032
                                  -------             -------

       Total assets              $622,348            $608,950
                                 ========            ========


                                        Period ending
                                 ---------------------------
                                 9/27/08            3/29/08
                                 -------            -------

    Liabilities & Stockholders'
     Equity
    -------------------------
    S/T debt & current
     maturities                    $4,434              $6,326
    Other current liabilities      81,100              91,351
                                   ------              ------
    Total current liabilities      85,534              97,677
    Long-term debt                  5,522               6,037
    Other long-term
     liabilities                   15,504              11,048
    Stockholders' equity          515,788             494,188
                                  -------             -------

       Total liabilities &
        equity                   $622,348            $608,950
                                 ========            ========



                         FREE CASH FLOW RECONCILIATION

                                                        Three Months Ended
                                                        ------------------
                                                        12/27/08  12/29/07
                                                        --------  --------

    GAAP CASH FLOW FROM OPERATIONS                       $30,881   $24,876
                                                         -------   -------

    Capital expenditures                                 (16,895)  (15,242)
    Proceeds from sale of property, plant and equipment       25     1,187
                                                              --     -----
    Net investment in property, plant and equipment      (16,870)  (14,055)
                                                         -------   -------

    Free Cash Flow                                       $14,011   $10,821
                                                         =======   =======


                                                         Nine Months Ended
                                                         -----------------
                                                        12/27/08  12/29/07
                                                        --------  --------

    GAAP CASH FLOW FROM OPERATIONS                       $72,658   $45,754
                                                         -------   -------

    Capital expenditures                                 (45,670)  (42,497)
    Proceeds from sale of property, plant and equipment    2,522     3,149
                                                           -----     -----
    Net investment in property, plant and equipment      (43,148)  (39,348)
                                                         -------   -------

    Free Cash Flow                                       $29,510    $6,406
                                                         =======    ======

Haemonetics Corporation Financial Summary

Reconciliation of Non-GAAP Measures

Haemonetics has presented supplemental non-GAAP financial measures as part of this earnings release. A reconciliation is provided below that reconciles each non-GAAP financial measure with the most comparable GAAP measure. The presentation of non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the most directly comparable GAAP measures. There are material limitations to the usefulness of non-GAAP measures on a standalone basis, including the lack of comparability to the GAAP financial results of other companies.

These measures are used by management to monitor the financial performance of the business, inform business decision making, and forecast future results. Performance targets for management are established based upon these non-GAAP measures. In the reconciliations below, we have removed restructuring costs from our GAAP expenses. These restructuring costs result from a significant transformation of our business during the third quarter and first nine months of our fiscal years 2009 and 2008. This transformation resulted in the formation of a shared service center in Europe, exiting various offices across Europe and Japan and, most recently, in repositioning our technical operations organization. We believe this information is useful for investors because it allows for an evaluation of the Company with a focus on the performance of our core operations.

Non-GAAP Gross Profit

The use of these non-GAAP measures allows management to monitor the level of total gross profits without the costs of our business transformation. We establish our budgets, forecasts, and performance targets on this basis.

Non-GAAP S,G&A and Non-GAAP Operating Expenses

The use of this non-GAAP measure allows management to monitor the ongoing level of spend that is necessary to support the business in a period when we are not transforming our business or completing an acquisition of in-process research and development. We establish our budgets, forecasts, and performance targets excluding these costs.

Non-GAAP Operating Income and Non-GAAP Income before Income Taxes

The use of these non-GAAP measures allows management to monitor the level of operating and total pre-tax profits without the costs of our business transformation. We establish our budgets, forecasts, and performance targets on this basis.

Non-GAAP Net Income and Earnings per Share

The use of these non-GAAP measures allows management to monitor the level of net income and earnings per share excluding both the costs of our business transformation, as well as any related tax effects. We establish our budgets, forecasts, and performance targets on this basis.


    Reconciliation of Non-GAAP Measures for the Third Quarter of FY09
     and FY08

                                                    --------  --------
                                                    12/27/08  12/29/07
                                                    --------  --------
    GAAP Gross Profit                                $78,296   $66,558
    Restructuring Costs                                    0         0
                                                        ----    ------
    Non-GAAP Gross Profit                            $78,296   $66,558
                                                     =======   =======

    GAAP S,G&A                                       $47,965   $41,432
    Restructuring Costs                                 (432)   (1,225)
                                                        ----    ------
    Non-GAAP S,G&A                                   $47,533   $40,207
                                                     =======   =======

    GAAP Operating Expenses                          $53,805   $46,961
    Restructuring Costs                                 (432)   (1,225)
                                                        ----    ------
    Non-GAAP Operating Expenses                      $53,373   $45,736
                                                     =======   =======

    GAAP Operating Income                            $24,491   $19,597
    Restructuring Costs                                  432     1,225
                                                        ----    ------
    Non-GAAP Operating income                        $24,923   $20,822
                                                     =======   =======

    GAAP Income before taxes                         $23,489   $20,892
    Restructuring Costs                                  432     1,225
                                                        ----    ------
    Non-GAAP Income before taxes                     $23,921   $22,117
                                                     =======   =======

    GAAP Net Income                                  $16,216   $14,354
    Restructuring Costs                                  432     1,225
    Tax benefit associated with
     Restructuring Costs                                (152)     (386)
                                                        ----    ------
    Non-GAAP Net Income                              $16,496   $15,193
                                                     =======   =======

    GAAP Net Income per common share
     assuming dilution                                 $0.62     $0.54
    Restructuring Costs after tax per
     common share assuming dilution                    $0.01     $0.03
                                                        ----    ------
    Non-GAAP Net Income per common share
     assuming dilution                                 $0.63     $0.57
                                                       =====     =====



    Reconciliation of Non-GAAP Measures for the First Nine Months of FY09
     and FY08

                                                    --------  --------
                                                    12/27/08  12/29/07
                                                    --------  --------
    GAAP Gross Profit                               $226,022  $187,940
    Restructuring Costs                                   72         0
                                                        ----    ------
    Non-GAAP Gross Profit                           $226,094  $187,940
                                                    ========  ========

    GAAP S,G&A                                      $141,687  $119,418
    Restructuring Costs                               (2,605)   (4,009)
                                                      ------    ------
    Non-GAAP S,G&A                                  $139,082  $115,409
                                                    ========  ========

    GAAP Operating Expenses                         $158,588  $137,950
    Restructuring Costs                               (2,605)   (4,009)
                                                      ------    ------
    Non-GAAP Operating Expenses                     $155,983  $133,941
                                                    ========  ========

    GAAP Operating Income                            $67,434   $49,990
    Restructuring Costs                                2,677     4,009
                                                      ------    ------
    Non-GAAP Operating income                        $70,111   $53,999
                                                     =======   =======

    GAAP Income before taxes                         $66,637   $55,932
    Restructuring Costs                                2,677     4,009
                                                      ------    ------
    Non-GAAP Income before taxes                     $69,314   $59,941
                                                     =======   =======

    GAAP Net Income                                  $45,365   $38,199
    Restructuring Costs                                2,677     4,009
    Tax benefit associated with Restructuring Costs     (939)   (1,341)
                                                      ------    ------
    Non-GAAP NET INCOME                              $47,103   $40,867
                                                     =======   =======

    GAAP Net Income per common share
     assuming dilution                                 $1.73     $1.43
    Restructuring Costs after tax per common share
     assuming dilution                                 $0.07     $0.10
                                                      ------    ------
    Non-GAAP Net Income per common share
     assuming dilution                                 $1.80     $1.53
                                                       =====     =====

    CONTACT:
    Julie Fallon
    Tel. (781) 356-9517
    Alternate Tel. (617) 320-2401
    fallon@haemonetics.com


'/>"/>
SOURCE Haemonetics Corporation
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Haemonetics Webcast Presentation
2. Keiko Hattori Joins Haemonetics as President of Haemonetics Japan
3. Haemonetics Appoints Executive Leadership of European Operations
4. Haemonetics Sets Date for Q3FY08 Earnings Release and Conference Call - January 31, 2008
5. Haemonetics(R) Reports Strong Results for Third Quarter Fiscal 2008 with Continued Double Digit Growth in Sales
6. Haemonetics(R) Software Solutions to Launch Application for Workflow Optimization in Blood Collection Centers
7. Haemonetics Sets Date for Fourth Quarter and Fiscal Year End 2008 Earnings Release and Conference Call - May 1, 2008
8. Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in Fiscal 2009
9. Haemonetics Chairman and CEO Adopts 10b5-1 Stock Trading Plan
10. Haemonetics Sets Date for First Quarter Fiscal Year 2009 Earnings Release and Conference Call - August 1, 2008
11. Haemonetics Announces Promotion of Brian Concannon to CEO Effective April 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... Transformation Solutions, LLC to help enterprises move workloads to the cloud. Cirracore ... connect to their cloud without traversing the Internet. Transformation Solutions (TSL Partners) ...
(Date:2/9/2016)... ... , ... Establishment Labs, a global breast implant and medical technology company, is ... Directors. , “We are honored to welcome David to our Board of ... Chacon Quiros, CEO of Establishment Labs. "David’s knowledge and experience will be invaluable to ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, ... Younkers department stores, announced it has raised $176,000 to benefit the Breast Cancer ... Cancer Center at the University of Iowa, The Lynn Sage Cancer Research Foundation, ...
(Date:2/9/2016)... ... ... METTLER TOLEDO has published a new guide entitled “Essential ... the techniques they use so they can more easily spot potential error sources ... to create a leaner overall lab experience. , The new guide offers ...
(Date:2/9/2016)... ... February 09, 2016 , ... United Methodist Communications ... of Prevention,” an animated video designed to prevent the next widespread ... the video are being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... ORLANDO, Florida , February 9, 2016 /PRNewswire/ ... QIA) today announced a collaboration with 10x Genomics ... sequencing (NGS), single-cell biology and bioinformatics. --> ... announced a collaboration with 10x Genomics to develop ... single-cell biology and bioinformatics. --> QIAGEN ...
(Date:2/9/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a ... and heart failure, today announced that it intends to offer ... in an underwritten public offering.  The offering is subject to ... as to whether or when the offering may be completed, ... offering.   --> --> ...
Breaking Medicine Technology: